Diligence memo · auto-generated · as of July 3, 2026

Colorado Therapeutics LLC

Colorado Therapeutics LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Colorado Therapeutics LLC operates in Pharma, based in BROOMFIELD.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Colorado Therapeutics LLC has raised $6.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.3M on 2015-06-11.

Most recent recorded round closed around 2017-04-03.

Valuation (modeled)modeled

Provath models Colorado Therapeutics LLC at approximately $80M (range $2.9M–$433M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.44× the median modeled value of Series A Pharma companies in 2016–2018 (14 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 22 months.

Last raise 9.2 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 59% of Pharma peers (310 compared).

Modeled value ranks above 63% of those peers.

Closest niche peers: Qool Therapeutics, Inc., SpringWorks Therapeutics, LLC, Caliber Therapeutics, Inc., Rodin Therapeutics, Inc., SmartPharm Therapeutics, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.